The non-series is dedicated to providing access to studies which are not otherwise a part of an explicit series.
You are here
3-Month Intreatment Data (DATOS-A-1993-1995-DS0004)
Study Series details:
Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A) was a multisite, prospective, community-based, longitudinal study of adolescents entering treatment. It was designed to evaluate the effectiveness of adolescent drug treatment by investigating the characteristics of the adolescent population, the structure and process of drug abuse treatment in adolescent programs, and the relationship of these factors with outcomes. Three major types or modalities of programs included in the study were chemical dependency or short-term inpatient (STI), therapeutic community or residential (RES), and outpatient drug-free (ODF). The adolescent battery of instruments included intake, intreatment, and follow-up questionnaires based largely on the DATOS adult study DRUG ABUSE TREATMENT OUTCOME STUDY (DATOS), 1991-1994: [UNITED STATES] instrument format, with considerable tailoring to the adolescent population. Clients entering treatment completed two comprehensive intake interviews (Intake 1 and Intake 2), approximately one week apart. This information is provided in Parts 1 and 2 of the data collection. These interviews were designed to obtain baseline data on drug use and other behaviors, such as illegal involvement, as well as information on background and demographic characteristics, education and training, mental health status, employment, income and expenditures, drug and alcohol dependence, health, religiosity and self-concept, and motivation and readiness for treatment. The one-, three-, and six-month intreatment interviews (Parts 3, 4, and 7) included items on treatment access, intreatment experience, and psychological functioning, as well as questions replicated from some of the domains in the Intake 1 and 2 questionnaires. The 12-month post-treatment follow-up interview (Part 5) included questions replicated from the previous interviews, and also included post-treatment status. Part 6 includes variables for time in treatment and interview availability indicators. The Measures Data (Part 8) were generated by using the Diagnostic and Statistical Manual of Mental Disorders (Rev. 3rd ed., DSM-III-R) (American Psychiatric Association, 1987). The variables in Part 8 give either the DSM-III-R level of dependence to a drug category or they describe whether the subject meets the DSM-III-R standard for a particular disorder. The 12-Month Follow-up Urine Result data (Part 9) provide the results from urine sample tests that were given to a sample of subjects at the time of the 12-Month Follow-up Interview. The urine test was used to ascertain the nature and extent of bias in the self-reports of the respondents. Urine specimens were tested for eight categories of drugs (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, methaqualone, opiates, and phencyclidine). The drugs covered in the study were alcohol, tobacco, marijuana (hashish, THC), cocaine (including crack), heroin, narcotics or opiates such as morphine, codeine, Demerol, Dilaudid, and Talwin, illegal methadone, sedatives and tranquilizers such as barbiturates and depressants, amphetamines or other stimulants such as speed or diet pills, methamphetamines, LSD, PCP, and other hallucinogens or psychedelics, and inhalants such as glue, gasoline, paint thinner, and aerosol sprays. The study also included drug of choice, frequency, and route of administration.